|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Mechanistically, we found that circFGFR3 promoted NSCLC cell invasion and proliferation via competitively combining with miR-22-3p to facilitate the galectin-1 (Gal-1), p-AKT, and p-ERK1/2 expressions.
|
30565694 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
In conclusion, the current study confirms the prognostic value of galectin-1 and identifies galectin-9Δ5 as novel potential prognostic markers in early stage NSCLC.
|
25259711 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
We did not observe significant associations between Gal-1 expression and relevant clinicopathologic features at diagnosis of NSCLC.
|
24560493 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
We found overexpression of galectin-1 in non-small cell lung cancer (NSCLC) cell lines.
|
22696230 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of secreted proteins of non-small cell lung cancer.
|
17094902 |
2006 |
|
Fibrosis, Liver
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the in vivo experimental results suggested that silencing the gene expression of Galectin‑1 improved liver fibrosis.
|
30365068 |
2019 |
|
Fibrosis, Liver
|
0.310 |
Biomarker
|
disease |
CTD_human |
Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis.
|
26396155 |
2016 |
|
Liver Cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis.
|
26396155 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Keloid
|
0.300 |
Biomarker
|
disease |
CTD_human |
Various classes of proteins were found either to be present or to be upregulated in keloid tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell β-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.
|
20128793 |
2010 |
|
Nephritis
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
|
11044214 |
2000 |
|
B-Cell Lymphomas
|
0.220 |
Biomarker
|
group |
BEFREE |
Oral administration of SKLB-850 considerably suppressed the tumor growth in BCL xenograft models (Ramos and HBL-1) in a dose-dependent manner.
|
29340070 |
2017 |
|
B-Cell Lymphomas
|
0.220 |
Biomarker
|
group |
RGD |
Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model.
|
16733672 |
2007 |
|
B-Cell Lymphomas
|
0.220 |
Biomarker
|
group |
BEFREE |
HBL-1 and HBL-2 appear useful for facilitating therapeutic investigations as well as immunologic and oncogenic studies in B-cell lymphomas.
|
3338018 |
1988 |
|
Lipoid nephrosis
|
0.200 |
Biomarker
|
disease |
RGD |
Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome.
|
19079321 |
2009 |
|
Cholestasis, Extrahepatic
|
0.200 |
Biomarker
|
disease |
RGD |
Factors released from cholestatic rat livers possibly involved in inducing bone marrow hepatic stem cell priming.
|
18225978 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gal-1 expression was also correlated with biomarkers of the tumor microenvironment.
|
31834627 |
2020 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Galectin-1 in endometrial adenocarcinoma was significantly different among tissues of different histological grades, pathological stages, degrees of myometrial infiltration, or lymph node metastasis (p > 0.05).
|
31487707 |
2020 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our results demonstrate that RACK1 stimulates tumor invasion and lymph node metastasis of cervical cancer via galectin-1 and imply that targeting RACK1/galectin-1 axis provides promising means for cervical cancer treatment.
|
31705928 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Together, our results demonstrate that RACK1 stimulates tumor invasion and lymph node metastasis of cervical cancer via galectin-1 and imply that targeting RACK1/galectin-1 axis provides promising means for cervical cancer treatment.
|
31705928 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The cell migration and invasion of HBL-52 cells was determined by transwell assay.
|
31786891 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, identification and inhibition of this protease may provide a new therapeutic tool for inhibiting SUSD2 and Gal-1's combined tumorigenic function in breast cancer.
|
31387209 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytotoxic behavior was tested in vitro against breast cancer (MDA-MB-231) and healthy epithelial cells (HEK-293 and HBL-100).
|
31571866 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis.
|
31778957 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our meta-analysis demonstrated that galectin-1 might be a useful common biomarker for predicting prognosis in patients with cancer.
|
30618160 |
2019 |